Cargando…

Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study

BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jin-Bao, Zeng, Ling-Cheng, Ren, Fei, Dang, Li-Yun, Luo, Hui, Wu, Yan-Qin, Yang, Xin-Jun, Li, Rong, Yang, Han, Xu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438796/
https://www.ncbi.nlm.nih.gov/pubmed/36060236
http://dx.doi.org/10.2147/IDR.S376177
_version_ 1784781903883141120
author Ma, Jin-Bao
Zeng, Ling-Cheng
Ren, Fei
Dang, Li-Yun
Luo, Hui
Wu, Yan-Qin
Yang, Xin-Jun
Li, Rong
Yang, Han
Xu, You
author_facet Ma, Jin-Bao
Zeng, Ling-Cheng
Ren, Fei
Dang, Li-Yun
Luo, Hui
Wu, Yan-Qin
Yang, Xin-Jun
Li, Rong
Yang, Han
Xu, You
author_sort Ma, Jin-Bao
collection PubMed
description BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an from 2017 to 2019. Risk factors associated with the treatment outcome were analyzed using multiple logistic regression. RESULTS: Of the 446 patients with MDR-TB included, 215 were cured, 84 completed treatment, 23 failed treatment, 108 were lost to follow-up, and 16 died. Unfavorable outcome risk factors were age >40 years (OR = 3.25, 95% CI = 2.12–4.98), male sex (OR = 2.53, 95% CI = 1.52–4.22), and re-treated tuberculosis (OR = 1.70, 95% CI = 1.11–2.61), whereas poor treatment outcome risk factors were age >40 years (OR = 5.51, 95% CI = 2.52–12.07), fluoroquinolones not used in the regimen (OR = 3.31, 95% CI = 1.45–7.51), and smear-positive (OR = 4.0, 95% CI = 1.47–10.8). CONCLUSION: In Xi’an, MDR-TB treatments with long-term regimens had low success rates, and age, sex, and tuberculosis treatment history were risk factors of MDR-TB treatment outcomes.
format Online
Article
Text
id pubmed-9438796
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94387962022-09-03 Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study Ma, Jin-Bao Zeng, Ling-Cheng Ren, Fei Dang, Li-Yun Luo, Hui Wu, Yan-Qin Yang, Xin-Jun Li, Rong Yang, Han Xu, You Infect Drug Resist Original Research BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an from 2017 to 2019. Risk factors associated with the treatment outcome were analyzed using multiple logistic regression. RESULTS: Of the 446 patients with MDR-TB included, 215 were cured, 84 completed treatment, 23 failed treatment, 108 were lost to follow-up, and 16 died. Unfavorable outcome risk factors were age >40 years (OR = 3.25, 95% CI = 2.12–4.98), male sex (OR = 2.53, 95% CI = 1.52–4.22), and re-treated tuberculosis (OR = 1.70, 95% CI = 1.11–2.61), whereas poor treatment outcome risk factors were age >40 years (OR = 5.51, 95% CI = 2.52–12.07), fluoroquinolones not used in the regimen (OR = 3.31, 95% CI = 1.45–7.51), and smear-positive (OR = 4.0, 95% CI = 1.47–10.8). CONCLUSION: In Xi’an, MDR-TB treatments with long-term regimens had low success rates, and age, sex, and tuberculosis treatment history were risk factors of MDR-TB treatment outcomes. Dove 2022-08-29 /pmc/articles/PMC9438796/ /pubmed/36060236 http://dx.doi.org/10.2147/IDR.S376177 Text en © 2022 Ma et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ma, Jin-Bao
Zeng, Ling-Cheng
Ren, Fei
Dang, Li-Yun
Luo, Hui
Wu, Yan-Qin
Yang, Xin-Jun
Li, Rong
Yang, Han
Xu, You
Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title_full Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title_fullStr Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title_full_unstemmed Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title_short Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
title_sort treatment outcomes and risk factors of multidrug-resistant tuberculosis patients in xi’an china, a retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438796/
https://www.ncbi.nlm.nih.gov/pubmed/36060236
http://dx.doi.org/10.2147/IDR.S376177
work_keys_str_mv AT majinbao treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT zenglingcheng treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT renfei treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT dangliyun treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT luohui treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT wuyanqin treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT yangxinjun treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT lirong treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT yanghan treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy
AT xuyou treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy